Daewoong Pharmaceutical’s “U.S. Appeal Court Urgent Temporary Disposition Citation ‘Nabota’ available for sale

▲ Nabota ⓒDaewoong Pharmaceutical

Daewoong Pharmaceutical announced on the 16th that an emergency motion to interim stay application for suspension of execution of an import ban order filed with the US Federal Circuit Appeals Court (CAFC) was cited on the 15th (US time).

It was quickly quoted three days after application for provisional injunction on the 12th. Accordingly, sales of the botulinum toxin drug Nabota (US export name: Jubo), which the U.S. International Trade Commission (ITC) ordered to ban imports for 21 months last December, can resume without a gap.

The bond conditions are the same as before, and, like the ITC deposit, the payee will be determined by the appeal court or the final decision of the Supreme Court.

If Ebolus wins the appeals trial or the Supreme Court final decision, the entire deposit is returned.

The emergency provisional injunction is valid until the appellate court’s decision to cite this provisional injunction, and the law firm representing Daewoong Pharmaceutical completed the application for provisional injunction on the 12th in the US local time so that it can be cited without deposit for the smooth sale of the bulletin.

A representative from Daewoong Pharmaceutical said, “We welcome Ebolus to continue its business even during the appeal period with CAFC’s rapid decision. Daewoong Pharmaceutical will correct all legal and factual errors in the existing ITC decision and win the appeals trial.” Said.